When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Tempus AI has announced that it is using the TIME Network to support Phase I trials and expedite site activation and ...

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock ...

BTIG analyst Mark Massaro has initiated coverage on Tempus AI (TEM), with a Buy rating and a price target of $60, implying 48 ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.78, ...

Tempus AI is a leader in applying AI solutions to cancer diagnosis. The company announced a new platform for speeding up the discovery of new drug targets. Since it's still unprofitable ...